SBIR and STTR Success Story for
INDOOR Biotechnologies Inc

(Information Posted/Updated on 07/08/2009)

INDOOR Biotechnologies Inc
1216 Harris Street
Charlottesville, VA  22903

Contact:    Dr. Martin D. Chapman
Phone:      434-984-2304
Fax:          434-984-2709
E-mail:      mdc@inbio.com
Web Site:  http://www.inbio.com/index.html

Project Title:  Fluorescent multiplex array for indoor allergens
Related Award(s):  N01-ES-55545
Technology Developed:
A fluorescent Multiplex ARray for Indoor Allergens (MARIA) has been developed which accurately measures exposure to eight common home allergens in a single test. This technology has greater sensitivity, accuracy and reproducibility than previous methods for allergen exposure assessment and is designed for epidemiologic studies of asthma and allergic diseases, and for monitoring indoor air quality. MARIA measures dust mite, cat, dog, rat, mouse and cockroach allergens.

Key Words:  allergen, microarray, exposure assessment, asthma, indoor allergens.
Uses of Technology/Products/Service:
Asthma and allergies strike one out of every four Americans and elevated allergen levels in the home are associated with asthma symptoms in allergic individuals. Asthmatics that have allergies may alleviate symptoms by reducing allergen exposure inside their homes. Indoor Biotechnologies’ scientists have developed breakthrough technology for measuring eight (or more) allergens in a single test using fluorescent multiplex laser array technology . The newly developed Multiplex Array for Indoor Allergens (MARIA) simultaneously measures the most common indoor allergens in a single dust sample with greater sensitivity, accuracy and reproducibility than previous methods. MARIA can analyze 200 individual dust samples for the presence of the eight most common indoor allergens in a day. This technology will enable allergen exposure to be monitored in homes, schools and the workplace and will be used in CDC and NIH studies of the causes of allergic asthma. MARIA technology will help to improve indoor air quality and will enable new procedures and devices for reducing allergen exposure to be developed.

Benefit to Company:
MARIA™ represents the next generation of allergen detection technology and was brought to market in February 2008. MARIA™ was developed in part using a $1.7M Small Business Innovation Research (SBIR) contract from the National Institutes of Environmental Health Sciences. The concept was brought from proof-of-principal to commercialization in under three years and truly represents a quantum leap in allergen monitoring. Indoor Biotechnologies has developed a State-of-the Art laboratory facility in Charlottesville as a result of the SBIR award and has hired four new employees.

MARIATM will dramatically improve the ability to measure asthma causing allergens in homes and businesses, and will be the cornerstone of Indoor Biotechnologies growth over the next five years.

How Product Was Commercialized:
Indoor Biotechnologies is the world leader in allergen detection systems and many of our products are unique. MARIA was launched in our on-line newsletter and at the recent annual meeting of the American Academy of Allergy Asthma and Immunology (Philadelphia, March 2008).

Other Comments Related to Company's Success Story:
Indoor biotechnologies has also demonstrated proof-of-principal for an immuno-diagnostic microarray for allergy diagnosis. This array measures IgE antibody to 10 allergens, as well as total IgE levels in human serum samples. Tests can be performed on as little as 15uL of serum which is a great advantage for pediatric studies.

peer -reviewed scientific papers on both MARIA and the allergy diagnostic array have been published, see: Earle et al, J Allergy Clin Immunol 2007; 119:428-33. king et al, J Allergy Clin Immunol 2007; 120:1126-31.

Past R&D and/or Sales from this Project:   $1.7M